Having trouble accessing articles? Reset your cache.

FDA approves Novartis' oral MS drug

FDA approved Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis (MS). The approval includes a REMS on the safe use and possible risks of

Read the full 302 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE